Vistagen Therapeutics Inc VTGN
$0.26 $0.01 (2.95%) 1D
Last Updated: Aug 17, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
VTGN Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Vistagen Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Vistagen Therapeutics Inc. Stock Analysis VTGN
United States Health Care Nano Cap Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 59 full-time employees. The company went IPO on 2010-10-18. The firm is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Vistagen Therapeutics Inc (VTGN) Chart
Financial Metrics & Statements of Vistagen Therapeutics Inc (VTGN)
FAQ's for Vistagen Therapeutics Inc (VTGN)
- As of August 2026, Vistagen Therapeutics Inc VTGN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Vistagen Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Vistagen Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Vistagen Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Vistagen Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Vistagen Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Vistagen Therapeutics Inc (VTGN)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
